Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors
April 13, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
April 06, 2021 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., April 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
March 04, 2021 07:00 ET
|
Landos Biopharma, Inc.
NX-13 was well tolerated with no reported serious adverse events All primary and secondary endpoints in the Phase 1 study of NX-13 were met Landos expects to initiate a Phase 1b trial of NX-13 in...
Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
February 23, 2021 16:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...
Landos Biopharma Announces Pricing of Initial Public Offering
February 03, 2021 20:13 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis
January 04, 2021 07:00 ET
|
Landos Biopharma, Inc.
-Once a day oral dosing with BT-11 induced placebo-adjusted clinical remission rates of up to 11.5% at week 12--A small subset of biologic-experienced patients also showed positive trends in clinical...
Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease
July 14, 2020 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., July 14, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
Landos Biopharma to Present at Two Upcoming Investor Conferences
May 12, 2020 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., May 12, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...
Landos Biopharma to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
March 24, 2020 16:05 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., March 24, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer, plans to present an...
Landos Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
February 26, 2020 07:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune...